Simultaneous analysis of cytokines and co-stimulatory molecules concentrations by ELISA technique andof probabilities of measurable concentrations of interleukins IL-2, IL-4, IL-5, IL-6, CXCL8 (IL-8), IL-10, IL-13 occurring in plasma of healthy blood donors

Martin, Klabusay; Viera, Kohutova; Petr, Coupek; Marie, Nenickova; Eva, Tesarova

doi:https://doi.org/10.1155/MI/2006/65237

Mediators of Inflammation

On this page

Abstract References Copyright Related Articles

Research Article | Open Access

Volume 2006 | Article ID 065237 | https://doi.org/10.1155/MI/2006/65237

Simultaneous analysis of cytokines and co-stimulatory molecules concentrations by ELISA technique andof probabilities of measurable concentrations of interleukins IL-2, IL-4, IL-5, IL-6, CXCL8 (IL-8), IL-10, IL-13 occurring in plasma of healthy blood donors

Klabusay Martin,¹Kohutova Viera,¹Coupek Petr,²Nenickova Marie,³and Tesarova Eva³

Received14 Apr 2006

Revised18 Jun 2006

Accepted19 Jun 2006

Published03 Oct 2006

Abstract

Background. The cytokine network remarkably influences homeostasis. There is not a complex analysis describing physiological values of soluble cytokines in healthy individuals. Methods. Authors used the ELISA method to detect soluble cytokines and costimulatory molecules simultaneously in the plasma of 30 blood donors. Results. Data are shown as (a range of concentrations; median) IL-2 (0–74.48 pg/mL; 0), IL-4 (0–65.18 pg/mL; 0), IL-5 (0–86.69 pg/mL; 0), IL-6 (0–73.17 pg/mL; 0), IL-8 (0–74.8 pg/mL; 0), IL-10 (0–12.6 pg/mL; 0), IL-13 (0–3.9 pg/mL; 0), sCD40L (0–3.5 ng/mL; 0), and TNF-α (0–67.6; 0). For the IL-6 receptor, the concentration was 75.89±35.83 ng/mL (average ± SD), sCD23 28.9±15.22 ng/mL, and TGFβ1 14.98±12.39 ng/mL. A special approach was taken for the analysis of values, which had median 0. A model for the probability of detectable level's occurrence for each interleukin was formulated with intervals of confidence. Conclusion. These results provide reference values for cytokine levels in the plasma of healthy individuals.

References

A W Thomson and M T Lotze, Eds., The Cytokine Handbook, Academic Press, London, UK, 4th edition, 2003.
S Singhal, R Powles, J Treleaven, C Horton, and J Mehta, “Long-term safety of GM-CSF (molgramostim) administration after allogeneic bone marrow transplantation for hematologic malignancies: five-year follow-up of a double-blind randomized placebo-controlled study,” Leukemia and Lymphoma, vol. 24, no. 3-4, pp. 301–307, 1997.
View at: Google Scholar
K-Y Chiang, L Lamb, J Clark, D Worthington-White, I Rich, and P J Henslee-Downey, “Assessment of G-CSF stimulated BM hematopoietic stem cells in normal donors,” Cytotherapy, vol. 4, no. 1, pp. 55–63, 2002.
View at: Publisher Site | Google Scholar
M Bewtra and G R Lichtenstein, “Infliximab use in Crohn's disease,” Expert Opinion on Biological Therapy, vol. 5, no. 4, pp. 589–599, 2005.
View at: Publisher Site | Google Scholar
L Etemad, E B Yu, and L A Wanke, “Dose adjustment over time of etanercept and infliximab in patients with rheumatoid arthritis,” Managed Care Interface, vol. 18, no. 4, pp. 21–27, 2005.
View at: Google Scholar
R Foa, M Massaia, S Cardona et al., “Production of tumor necrosis factor-alpha by B-cell chronic lymphocytic leukemkia cells: a possible regulatory role of TNF in the progression of the disease,” Blood, vol. 76, no. 2, pp. 393–400, 1990.
View at: Google Scholar
J W Eklund and T M Kuzel, “Interleukin-2 in the reatment of renal cell carcinoma and malignant melanoma,” Cancer Treatment and Research, vol. 126, pp. 263–287, 2005.
View at: Google Scholar
W Hsu, M S Lesniak, B Tyler, and H Brem, “Local delivery of interleukin-2 and adriamycin is synergistic in the treatment of experimental malignant glioma,” Journal of Neuro-Oncology, vol. 74, no. 2, pp. 135–140, 2005.
View at: Publisher Site | Google Scholar
G Meloni, M Vignetti, C Andrizzi, S Capria, R Foa, and F Mandelli, “Interleukin-2 for the treatment of advanced acute myelogenous leukemia patients with limited disease: updated experience with 20 cases,” Leukemia and Lymphoma, vol. 21, no. 5-6, pp. 429–435, 1996.
View at: Google Scholar
W Krenger and J LM Ferrara, “Dysregulation of cytokines during graft-versus-host disease,” Journal of Hematotherapy, vol. 5, no. 1, pp. 3–14, 1996.
View at: Google Scholar
J K Garrett, S C Jameson, B Thomson et al., “Anti-interleukin-5 (mepolizumab) therapy for hypereosinophilic syndromes,” Journal of Allergy and Clinical Immunology, vol. 113, no. 1, pp. 115–119, 2004.
View at: Publisher Site | Google Scholar
W J Jordan, P A Brookes, R M Szydlo, J M Goldman, R I Lechler, and M A Ritter, “IL-13 production by donor T cells is prognostic of acute graft-versus-host disease following unrelated donor stem cell transplantation,” Blood, vol. 103, no. 2, pp. 717–724, 2004.
View at: Google Scholar
X Thomas, C Hirschauer, J Troncy et al., “Serum interleukin-6 levels in adult acute myelogenous leukemia: relationship with disease characteristics and outcome,” Leukemia and Lymphoma, vol. 24, no. 3-4, pp. 291–300, 1997.
View at: Google Scholar
A Wierzbowska, H Urbańska-Ryś, and T Robak, “Circulating IL-6-type cytokines and sIL-6R in patients with multiple myeloma,” British Journal of Haematology, vol. 105, no. 2, pp. 412–419, 1999.
View at: Google Scholar
A Gause, D Spickermann, S Klein, V Diehl, and M Pfreundschuh, “Elevation of circulating IL-6 in patients with acute non-lymphocytic leukemia,” European Journal of Haematology, vol. 53, no. 3, pp. 178–180, 1994.
View at: Google Scholar
R Lai, S O'Brien, T Maushouri et al., “Prognostic value of plasma interleukin-6 levels in patients with chronic lymphocytic leukemia,” Cancer, vol. 95, no. 5, pp. 1071–1075, 2002.
View at: Publisher Site | Google Scholar
M Herold, F Schmalzl, and H Zwierzina, “Increased serum interleukin 6 levels in patients with myelodysplastic syndromes,” Leukemia Research, vol. 16, no. 6-7, pp. 585–588, 1992.
View at: Google Scholar
T Watanabe, Y Kawano, S Kanamaru et al., “Endogenous interleukin-8 (IL-8) surge in granulocyte colony-stimulating factor-induced peripheral blood stem cell mobilization,” Blood, vol. 93, no. 4, pp. 1157–1163, 1999.
View at: Google Scholar
E F Kamper, A D Papaphilis, M K Angelopoulou et al., “Serum levels of tetranectin, intercellular adhesion molecule-1 and interleukin-10 in B-chronic lymphocytic leukemia,” Clinical Biochemistry, vol. 32, no. 8, pp. 639–645, 1999.
View at: Publisher Site | Google Scholar
Z Y Lu, X G Zhang, C Rodriguez et al., “Interleukin-10 is a proliferation factor but not a differentiation factor for human myeloma cells,” Blood, vol. 85, no. 9, pp. 2521–2527, 1995.
View at: Google Scholar
T A Wynn, “IL-13 effector functions,” Annual Review of Immunology, vol. 21, pp. 425–456, 2003.
View at: Google Scholar
E Fuhrmann-Benzakein, M N Ma, L Rubbia-Brandt et al., “Elevated levels of angiogenic cytokines in the plasma of cancer patients,” International Journal of Cancer, vol. 85, no. 1, pp. 40–45, 2000.
View at: Publisher Site | Google Scholar
M A Sarmiento, M F Palacios, M P Scolnik et al., “Evolution of chronic lymphocytic leukemia. Predictive value of immunophenotype, sCD23 and morphology,” Medicina, vol. 62, no. 4, pp. 305–312, 2002.
View at: Google Scholar
J D Schwarzmeier, M Shehata, M Hilgarth et al., “The role of soluble CD23 in distinguishing stable and progressive forms of B-chronic lymphocytic leukemia,” Leukemia and Lymphoma, vol. 43, no. 3, pp. 549–554, 2002.
View at: Publisher Site | Google Scholar
K Clodi, Z Asgary, S Zhao et al., “Coexpression of CD40 and CD40 ligand in B-cell lymphoma cells,” British Journal of Haematology, vol. 103, no. 1, pp. 270–275, 1998.
View at: Publisher Site | Google Scholar
A Toren, D Novick, A Ackerstein, R Or, S Slavin, and A Nagler, “Soluble IL-6 receptors (sIL-6R) in hematological patients receiving immunotherapy with IL-2/IFN- $\alpha$ or donor lymphocytes following bone marrow transplantation,” Bone Marrow Transplantation, vol. 18, no. 4, pp. 721–724, 1996.
View at: Google Scholar

Copyright

Copyright © 2006 Klabusay Martin et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

PDF Download Citation Order printed copies

Views

623

Downloads

1455

Citations